| 2024-11-07 | 10-Q | 10.4 | Stock and Asset Purchase Agreement, dated July 31, 2024, between Emergent BioSolutions Canada Inc., a wholly owned subsidiary of the Company, and BTG International Inc., a wholly owned subsidiary of SERB Pharmaceuticals. |
|---|
| 2024-10-02 | 8-K | 10.1 | Credit Agreement, dated as of September 30, 2024, by and among Emergent BioSolutions Inc., certain of its subsidiaries, as borrowers, the lenders party thereto from time to time, and Wells Fargo Bank, National Association, as the agent. |
|---|
| 2024-09-03 | 8-K | 10.3 | Form of Subscription Agreement, dated August 30, 2024, between Emergent BioSolutions Inc. and the Subscribing Entities. |
|---|
| 2024-09-03 | 8-K | 10.2 | Form of Warrant (included in Exhibit 10.2). |
|---|
| 2024-09-03 | 8-K | 10.1 | Credit Agreement, dated as of August 30, 2024, by and among Emergent BioSolutions Inc., the lenders from time to time party thereto and OHA Agency LLC, as administrative agent.† |
|---|
| 2024-07-02 | 8-K | 10.2 | Modification No. 17, effective June 26, 2024, to the BARDA AV7909 Contract. |
|---|
| 2024-07-02 | 8-K | 10.1 | Modification No. 12, effective June 28, 2024, to the ACAM2000 Contract. |
|---|
| 2024-05-29 | 8-K | 10.1 | Emergent BioSolutions Inc. Amended and Restated Stock Incentive Plan |
|---|
| 2024-05-02 | 10-Q | 10.5 | Modification No. 2, effective March 21, 2024 to the BioThrax IDIQ Contract. |
|---|
| 2024-05-02 | 10-Q | 10.4 | Modification No. 1, effective February 13, 2024 to the BioThrax IDIQ Contract. |
|---|
| 2024-05-02 | 10-Q | 10.3 | Delivery Order 1, effective January 22, 2024 to the BioThrax IDIQ Contract. |
|---|
| 2024-05-02 | 10-Q | 10.2 | Award/Contract, effective January 9, 2024 (BioThrax IDIQ Contract), from the United States Department of Defense to Emergent Biodefense Operations Lansing LLC. |
|---|
| 2024-05-02 | 10-Q | 10.1 | Seventh Amendment to the Amended and Restated Credit Agreement, dated April 29, 2024, among Emergent BioSolutions Inc., the guarantors party thereof, the lenders party thereof, and Wells Fargo Bank, National Association, as administrative agent. |
|---|
| 2024-05-01 | 8-K | 10.1 | Modification No. 11, effective April 29, 2024, to the ACAM2000 Contract. |
|---|
| 2024-04-26 | 8-K | 10.1 | Form of Amendment to Letter Agreement, dated April 23, 2024. |
|---|
| 2024-03-08 | 10-K | 10.224 | Emergent BioSolutions Compensation Recovery Policy, effective October 26, 2023. |
|---|
| 2024-03-08 | 10-K | 10.93 | Modification No. 8, effective November 21, 2022, to the ACAM2000 Contract. |
|---|
| 2024-03-08 | 10-K | 10.92 | Modification No. 7, effective October 6, 2022, to the ACAM2000 Contract. |
|---|
| 2024-03-08 | 10-K | 10.81 | Modification No. 16, effective November 21, 2023, to the BARDA AV7909 Contract. |
|---|
| 2024-03-08 | 10-K | 10.80 | Modification No. 15, effective October 6, 2023, to the BARDA AV7909 Contract. |
|---|
| 2024-03-08 | 10-K | 10.6 | Fifth Amendment to Amended and Restated Credit Agreement, dated July 14, 2023 |
|---|
| 2024-03-06 | 8-K | 10.1 | Forbearance Agreement and Sixth Amendment to Amended and Restated Credit Agreement, dated February 29, 2024, among Emergent BioSolutions Inc., the guarantors party thereof, the lenders party thereof, and Wells Fargo Bank, National Association, as administrative agent. |
|---|
| 2024-02-21 | 8-K | 10.1 | Executive Agreement, dated February 19, 2024 between Emergent BioSolutions Inc. And Joseph Papa. |
|---|